glp-1 diarrhea class action in louisiana At least 3,000 patients have filed lawsuits against the companies behind GLP -1 weight loss drugs, alleging severe health risks, including blindness. NewsNation's Brooke Shafer has the story on "Morning America." MonaLean™ | Plant-Based GLP-1 Signaling
Description
With respect to body weight, cotadutide at 200 g led to weight loss of 3.22 kg on average versus 3.33 kg with liraglutide, but the 300 g dose led to weight loss of 5.02 kg albeit with far higher gastrointestinal adverse event rates than liraglutide (85)

CrossRef Zhang L, Chen X, Xu Y, et al

So, the questions remain

Exenatide was approved by the US FDA in 2005 and by the European Medicines Agency (EMA) in 2006

The FDA sets the floor

El objetivo principal fue medir: El porcentaje de cambio de peso corporal desde el comienzo del estudio hasta la semana 13
